Clinical Trials Browser

Interventional × Breast Carcinoma In Situ × Tablets × Clear all

NCT06033092 2025-08-28

TOLERANT

Phase 2 Active not recruiting

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating